c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pathology and Oncology Research

• Publication date

  2010-02-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12253-010-9247-9PMID 20177846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas

  2010cited by this paper
• Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome

  2009cited by this paper
• DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors: A Study of 1840 Cases

  2009cited by this paper
• Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

  2008cited by this paper
• Keratin-positive gastrointestinal stromal tumor of the stomach mimicking gastric carcinoma: diagnosis confirmed by c-kit mutation analysis.

  2008cited by this paper
• Expression of c-kit Protein and Mutational Status of the c-kit Gene in Osteosarcoma and Their Clinicopathological Significance

  2008cited by this paper
• Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

  2008cited by this paper
• A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation

  2007cited by this paper
• CD117 (c-kit) expression in human hepatocellular carcinoma.

  2007cited by this paper
• Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.

  2007cited by this paper
• A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer

  2006cited by this paper
• Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

  2006cited by this paper
• Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated‐type breast carcinomas with ‘stem‐cell‐like’ features

  2005cited by this paper
• KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.

  2005cited by this paper
• A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

  2005cited by this paper
• KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations

  2004cited by this paper
• Signal transduction via the stem cell factor receptor/c-Kit

  2004cited by this paper
• Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients

  2004cited by this paper
• Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues

  2004cited by this paper
• Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias

  2004cited by this paper
• Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment

  2004cited by this paper
• Prevalence of KIT expression in human tumors.

  2004cited by this paper
• KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

  2004cited by this paper
• Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium

  2003cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Diagnosis of gastrointestinal stromal tumors: A consensus approach.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.

  2002cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• The biology of stem cell factor and its receptor C-kit.

  1999cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.

  1998cited by this paper
• Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues.

  1996cited by this paper
• Expression of c-kit and kit ligand proteins in normal human tissues.

  1994cited by this paper
• Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues.

  1993cited by this paper
• Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

  1992cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family

  1986cited by this paper

• Patterns of expression of VEGFR2, PDGFRs and c-Kit in pediatric patients with high grade non-rhabdomyosarcoma soft tissue sarcoma

  2024cites this paper
• Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis

  2023cites this paper
• In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC—Application towards Cancer Therapeutics

  2022cites this paper
• Colon cancer organoids using monoclonal organoids established in four different lesions of one cancer patient reveal tumor heterogeneity and different real-time responsiveness to anti-cancer drugs.

  2022cites this paper
• A Rare Case of a Giant Retroperitoneal Gastrointestinal Stromal Tumor of Malignant Potential

  2021cites this paper
• 99m-Technetium-Pertechnetat- und 99m-Technetium-Sestamibi-Szintigrafie zur Darstellung von hypofunktionellem Schilddrüsengewebe und Staging bei einem Hund mit Schilddrüsenkarzinom

  2021cites this paper
• TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis

  2021cites this paper
• Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

  2021cites this paper
• Modern Imaging Technologies of Mast Cells for Biology and Medicine (Review)

  2021cites this paper
• CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance

  2021cites this paper
• Expression frequency of c-kit isoforms and its prognostic potential in canine mammary tumours.

  2020cites this paper
• Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma.

  2020cites this paper
• Immunohistochemical study of CD117 in various cutaneous melanocytic lesions

  2020cites this paper
• Caracterización molecular de los carcinosarcomas de endometrio.

  2018cites this paper
• Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer

  2018cites this paper
• CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance

  2018cites this paper
• Giant gastrointestinal stromal tumour of the stomach: a case report with surgical treatment.

  2018cites this paper
• CTC Marker CD117/c-kit Represents a Prostate Cancer Stem-Like Subpopulation Driving Progression, Migration, and TKI Resistance

  2018cites this paper
• Giant Gastrointestinal Stromal Tumor of the Stomach

  2018cites this paper
• Altered expression of cytokeratin 7 and CD117 in transitional mucosa adjacent to human colorectal cancer

  2017influential citation
• Accuracy of c-KIT in Lung Cancer Prognosis; a Systematic Review Protocol" instead of c-KIT Expression in Lung Cancer Prognostic Evaluation - a Systematic Review Protocol.

  2016cites this paper
• Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib

  2016cites this paper
• Survival prediction via partial ordering in feature space and sample space

  2016cites this paper
• KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

  2015cites this paper
• Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma

  2015cites this paper
• CD 117 + cells in the circulation are predictive of advanced prostate cancer

  2015cites this paper
• Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy

  2015cites this paper
• Prognostic value of CD 117 in cancer : a meta-analysis

  2014cites this paper
• Prognostic value of CD117 in cancer: a meta-analysis.

  2014cites this paper
• CD117+ cells in the circulation are predictive of advanced prostate cancer

  2014cites this paper
• Ruptured gastric stromal tumour into gastric lumen with an abscess

  2014cites this paper
• c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis.

  2013cites this paper
• Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer

  2013cites this paper
• Oncogene alterations in endometrial carcinosarcomas.

  2013cites this paper
• Molecular and Cellular Pathobiology c-Kit Is Suppressed in Human Colon Cancer Tissue and Contributes to L 1-Mediated Metastasis

  2013cites this paper
• Contributes to L 1-Mediated Metastasis c-Kit Is Suppressed in Human Colon Cancer Tissue and

  2013cites this paper
• A rare giant gastrointestinal stromal tumor of the stomach traversing the upper abdomen: a case report and literature review

  2012cites this paper
• Chapter 37 – Tumors of the Pineal Region

  2012cites this paper
• Can the presence of C-Kit-positive hepatic progenitor cells in chronic hepatitis C have a role in the follow-up of the disease?

  2012cites this paper
• Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican‐3 in malignant germ cell tumors of the ovary

  2012cites this paper
• Assessment of prognostic markers in benign and malignant melanocytic tumours

  2011cites this paper